Name:

Deplera®

Type of medical product:

Protein based

Novelty:

Biosimilar

Field:

Oncology

Indications for use:

B-cell non-Hodgkin’s lymphomas

Status:

Clinical trial permission has been granted

The agent is synthetic (gene-engineered) chimeric G1 murine/human monoclonal antibody, specific for CD20 antigen detected at the surface of normal and malignant B-lymphocytes. It is a biosimilar for Mabtera® (Roche, Switzerland). Applications: B-cell non-Hodgkin’s lymphomas, chronic lymphocytic leukemia, rheumatoid arthritis, Wegener's granulomatosis.
Non-Hodgkin’s lymphomas is a group of 30 disorders of lymphatic system.